Tunneling nanotube-mediated mitochondrial transfer (TNT-mediated mitochondrial transfer)

Tunneling nanotubes (TNTs) are thin, F-actin-rich membranous structures that connect cells over distances of tens of microns, facilitating direct intercellular transfer of cytoplasmic components, including intact mitochondria[3][4][6]. TNT-mediated mitochondrial transfer enables healthy or donor cells to rescue recipient cells with damaged mitochondria by donating functional mitochondria, thereby restoring cellular energy production, promoting survival, and modulating processes such as apoptosis, differentiation, and immune response[1][2][6]. This process is increasingly recognized for its role in neuroprotection, cardiovascular repair, and cancer biology, where TNTs may help damaged or drug-sensitive cells escape cell death, but may also be exploited for pathological cell survival[1][4]. The formation of TNTs involves dynamic remodeling of the actin cytoskeleton and is regulated by proteins such as TNFAIP2, RalA, MICAL2PV, and others[5][6]. There are no established direct drugs, clinical biomarkers, or specific safety monitoring parameters for TNT-mediated mitochondrial transfer; current understanding is mechanistic and preclinical[6]. Because this entry describes a process rather than a discrete molecular target, it should not be classified as a canonical drug target.

Other names

Tunneling nanotube mitochondrial transferIntercellular mitochondrial transfer via TNTsMitochondrial transfer by tunneling nanotubes

Not applicable for specific drugs, but general mechanisms that could impact the process include disruption of actin polymerization (which blocks TNT formation and thus prevents mitochondrial transfer)[4][5]. Inhibition of TNT formation by targeting associated regulatory proteins (such as TNFAIP2, RalA, MICAL2PV)[5][6].